Celltrion Inc., of Incheon, South Korea, reported 54-week results from the extended Phase I PLANETAS study testing CT-P13 in patients with ankylosing spondylitis, showing CT-P13's comparable pharmacokinetics and efficacy to Rituxan (infliximab, Roche AG and Biogen Idec Inc

Apart from Royalty and, perhaps, Weston, Mass.-based Biogen Idec Inc., which could decide to buy its way out of future royalty obligations, there are no other obvious takers

Since going hostile, Royalty has upped its bid, with the revised offer comprising $13 per share in cash, with an additional $2.50 per share in contingent value rights linked to the future performance of multiple sclerosis drug Tysabri (natalizumab), in which Elan has a royalty position from Biogen Idec Inc., of Weston, Mass

Company (Location) Product Description Indication Status Date AUTOIMMUNE Biogen Idec Inc. (Weston, Mass.) Plegridy Peginterferon beta-1a Multiple sclerosis Submitted a BLA 5/22/13 CANCER Algeta ASA (Oslo, Norway) and Bayer AG (Leverkusen, Germany) Xofigo Radium Ra 223 dichloride...an oncolytic immunotherapy Hepatocellular carcinoma FDA granted orphan drug status 5/10/13 Seattle Genetics Inc. (Bothell, Wash.) Adcetris Brentuximab vedotin Relapsed Hodgkin lymphoma and systemic anaplastic large-cell

Celltrion Inc., of Incheon, South Korea, reported 54-week results from the extended Phase I PLANETAS study testing CT-P13 in patients with ankylosing spondylitis, showing CT-P13's comparable pharmacokinetics and efficacy to Rituxan (infliximab, Roche AG and Biogen Idec Inc

Pfizer's collaboration with CytomX closely follows last month's fizzle of the Phase III trial with inotuzumab ozogamicin, the ADC composed of a monoclonal antibody targeting CD22, administered in combination with Rituxan (rituximab, Roche AG and Biogen Idec Inc.), in relapsed or refractory CD22-positive aggressive non-Hodgkin's lymphoma (NHL). (See BioWorld Today, May 22, 2013.) NHL work with the compound stopped after an independent data monitoring committee concluded, during a scheduled

Immunomedics Inc., of Morris Plains, N.J., reported that adding two doses of epratuzumab labeled with the radioisotope yttrium-90 to a combination with Rituxan (rituximab, Roche AG and Biogen Idec Inc.) and CHOP chemotherapy (R-CHOP) appeared to improve elderly diffuse large B-cell lymphoma patients' responses to treatment

launch of Xofigo injection to treat castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease 5/31/13 Curis Inc. (Lexington, Mass.) Genentech Inc. (South San Francisco; unit of Roche AG) $4 For the Australian approval of Erivedge (vismodegib) for metastatic basal cell carcinoma, or locally advanced basal cell carcinoma where surgery and/or radiation therapy are not appropriate 5/13/13 Isis Pharmaceuticals Inc. (Carlsbad, Calif.) Biogen Idec Inc

Pfizer's collaboration with CytomX closely follows last month's fizzle of the Phase III trial with inotuzumab ozogamicin, the ADC composed of a monoclonal antibody targeting CD22, administered in combination with Rituxan (rituximab, Roche AG and Biogen Idec Inc.), in relapsed or refractory CD22-positive aggressive non-Hodgkin's lymphoma (NHL). (See BioWorld Today, May 22, 2013.) NHL work with the compound stopped after an independent data monitoring committee concluded, during a scheduled

The authors tested monoclonals Herceptin (trastuzumab, Roche AG), Erbitux (cetuximab, Eli Lilly and Co.) and Rituxan (rituximab, Roche and Biogen Idec Inc

Biogen Idec Inc., of Weston, Mass., appointed Spyros Artavanis-Tsakonas chief scientific officer

Biogen Idec Inc.'s hiccup in the European launch of Tecfidera (dimethyl fumarate), known as BG-12 in trials, sparked a mild kerfuffle among analysts trying to figure out the status of intellectual property (IP) protection for the multiple sclerosis (MS) therapy approved in the U.S

Manufacturing and royalty revenues from Ampyra/Fampyra (dalfampridine, Acorda Pharmaceuticals Inc. and Biogen Idec Inc.) were $65 million, compared to $24.6 million for the previous fiscal year, and royalty revenue from Bydureon (exenatide, Amylin Pharmaceuticals Inc.) was $16.4 million compared to $1.5 million for the prior fiscal year...The new offer represented a value of $4.6 billion for Elan's Tysabri (natalizumab) royalty, a 42 percent premium to the $3.25 billion at which Elan sold

Company Company Deal Value Biogen Idec Inc

Manufacturing and royalty revenues from Ampyra/Fampyra (dalfampridine, Acorda Pharmaceuticals Inc. and Biogen Idec Inc.) were $65 million, compared to $24.6 million for the previous fiscal year, and royalty revenue from Bydureon (exenatide, Amylin Pharmaceuticals Inc.) was $16.4 million compared to $1.5 million for the prior fiscal year

The new offer represented a value of $4.6 billion for Elan's Tysabri (natalizumab) royalty, a 42 percent premium to the $3.25 billion at which Elan sold approximately half of its interest in Tysabri to Biogen Idec Inc., of Weston, Mass

Another product candidate, PRT2607, is partnered with Biogen Idec Inc

At the start of May, Elan was just about completing its transition from being a neurology-focused biotechnology firm to becoming an acquirer of companies and assets, with almost $2 billion of cash on a debt-free balance sheet and a steady income from royalties on sales of the blockbuster multiple sclerosis drug Tysabri (natalizumab), which is now under the sole control of Biogen Idec Inc., of Weston, Mass. (See BioWorld International, May 1, 2013.) Shareholders gave the latest news a very